Dianthus Therapeutics, Inc. has entered into an underwriting agreement to sell 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999 each, aiming to raise approximately $673.5 million in net proceeds.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.